Cardiome enters into distribution deal for Brinavess, shares +4.9%


Cardiome Pharma (CRME +4.9%) says its Correvio subsidiary signed a distribution deal for its atrial fibrillation treatment Brinavess (vernakalant IV) in the Swedish market; financial details were not been disclosed.

Coupled with recent data that demonstrated conversion to normal sinus rhythm in ~70% of patients treated with Brinavess who were experiencing atrial fibrillation for less than 48 hours, CRME expects Sweden will be a key market for the treatment's growth.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs